Yingjie Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yingjie Xu has a total of 207 co-authors. Here are the top co-authors by number of shared publications:
- Wen Yang
Cancer Research Center, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China
17 shared publications Yu Zhang
Department of Biochemistry and Molecular Cell Biology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
9 shared publicationsXiang Yu
Department of Biochemistry and Molecular Cell Biology, Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Shanghai Jiao Tong University School of Medicine 2 , Shanghai, China
6 shared publicationsJia Xia
Department of Nephrology, Renji Hospital
5 shared publicationsJiahui Wang
Department of Biochemistry and Molecular Cell Biology, Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Shanghai Jiao Tong University School of Medicine, Shanghai, PR China
5 shared publicationsJiahui Zhang
Department of Biochemistry and Molecular Cell Biology, Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Shanghai Jiao Tong University School of Medicine, Shanghai, China
5 shared publications
Latest Publications
- Open Access
- 25 August 2026
- Published by Springer Nature in Scientific Reports
Overexpression of KRAS-Q25A mutant with enhanced GTPase activity inhibits the progression of KRAS-G12D colorectal cancer
- 25 August 2026
- Published by Springer Nature in Scientific Reports
Open AccessOverexpression of KRAS-Q25A mutant with enhanced GTPase activity inhibits the progression of KRAS-G12D colorectal cancer
- Open Access
- 17 May 2026
- Published by Wiley in The FASEB Journal
- Vol. 40 (10) , e71904
Intravesical Delivery of P21 mRNA –Loaded Lipid Nanoparticles as a Tumor Suppressor Replacement Therapy for Bladder Cancer
Bladder cancer is characterized by high recurrence rates and limited long‐term benefit from current intravesical therapies, highlighting the need for alternative localized treatment strategies. Among tumor suppressors altered in bladder cancer, CDKN1A , which encodes the cyclin‐dependent kinase inhibitor p21, is recurrently inactivated and downregulated, supporting its potential as a target for tumor suppressor replacement. Here, we developed a non‐viral therapeutic strategy based on chemically modified p21 mRNA encapsulated in lipid nanoparticles (p21‐LNP) for intravesical delivery. Public dataset analysis, tissue microarray staining, and cell line validation showed that p21 expression decreases during bladder cancer progression and that endogenous p21 protein levels are very low in bladder cancer cells. In vitro, synthetic p21 mRNA achieved robust nuclear p21 expression and markedly suppressed bladder cancer cell proliferation, viability, and clonogenicity. Mechanistically, p21 restoration reduced retinoblastoma protein (Rb) phosphorylation, decreased Cyclin E, Cyclin B, and proliferating cell nuclear antigen (PCNA) expression, increased γ‐H2A.X accumulation, and promoted apoptosis. The resulting p21‐LNP showed favorable physicochemical properties for intravesical administration. In vivo, reporter mRNA‐LNP mediated strong bladder‐localized protein expression with limited and transient systemic distribution. In an orthotopic bladder cancer mouse model, repeated intravesical administration of p21‐LNP significantly suppressed tumor growth, restored p21 expression in bladder tissues, and preserved urothelial architecture without obvious adverse effects. Together, these findings establish intravesical delivery of p21 mRNA‐LNP as a clinically compatible strategy for localized tumor suppressor replacement therapy in bladder cancer.
- 17 May 2026
- Published by Wiley in The FASEB Journal
- Vol. 40 (10) , e71904
Open AccessIntravesical Delivery of P21 mRNA –Loaded Lipid Nanoparticles as a Tumor Suppressor Replacement Therapy for Bladder Cancer
Bladder cancer is characterized by high recurrence rates and limited long‐term benefit from current intravesical therapies, highlighting the need for alternative localized treatment strategies. Among tumor suppressors altered in bladder cancer, CDKN1A , which encodes the cyclin‐dependent kinase inhibitor p21, is recurrently inactivated and downregulated, supporting its potential as a target for tumor suppressor replacement. Here, we developed a non‐viral therapeutic strategy based on chemically modified p21 mRNA encapsulated in lipid nanoparticles (p21‐LNP) for intravesical delivery. Public dataset analysis, tissue microarray staining, and cell line validation showed that p21 expression decreases during bladder cancer progression and that endogenous p21 protein levels are very low in bladder cancer cells. In vitro, synthetic p21 mRNA achieved robust nuclear p21 expression and markedly suppressed bladder cancer cell proliferation, viability, and clonogenicity. Mechanistically, p21 restoration reduced retinoblastoma protein (Rb) phosphorylation, decreased Cyclin E, Cyclin B, and proliferating cell nuclear antigen (PCNA) expression, increased γ‐H2A.X accumulation, and promoted apoptosis. The resulting p21‐LNP showed favorable physicochemical properties for intravesical administration. In vivo, reporter mRNA‐LNP mediated strong bladder‐localized protein expression with limited and transient systemic distribution. In an orthotopic bladder cancer mouse model, repeated intravesical administration of p21‐LNP significantly suppressed tumor growth, restored p21 expression in bladder tissues, and preserved urothelial architecture without obvious adverse effects. Together, these findings establish intravesical delivery of p21 mRNA‐LNP as a clinically compatible strategy for localized tumor suppressor replacement therapy in bladder cancer.
- 13 April 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (16) , 12321-12346
Self-Assembling Enveloped Virus-Mimicking Particle for Extrahepatic Targeting mRNA Delivery
Precise and efficient delivery of messenger RNA (mRNA) to extrahepatic tissues remains a major challenge in advancing mRNA-based therapeutics. Although enveloped viruses and virus-like particles (VLPs) serve as natural RNA delivery systems with varied extrahepatic targeting capabilities, their clinical translation is often hampered by bottlenecks in tunability, safety, immunogenicity, and scalability. Here, we developed a bottom-up self-assembling enveloped virus-mimicking particle (EVMP) composed of highly simplified yet high-performance virus-mimicking peptide (VMP) and tissue-targeting envelope phospholipids. By employing virtual screening via molecular dynamics simulation, directed evolution via key assembling domain mutation, strategic N-terminal fatty acylation modifications, and precise adjustments to envelope phospholipid composition, we achieved high-efficiency delivery of mRNA to organs such as the lungs and spleen. Notably, the optimized lung-targeted EVMP achieved transfection in 37% of total lung cells, including 73% of endothelial cells and 28% of immune cells. In a metastatic lung tumor model, the lead EVMP loaded with IL-12 mRNA effectively suppressed tumor progression. Notably, EVMP demonstrated excellent long-term biosafety and the capacity for repeated administration, owing to their minimal immunogenic profile. This biomimetic virus-mimicking nanoplatform represents a transformative advance in mRNA delivery technologies, enabling effective and safe mRNA-based therapy for extrahepatic diseases. Furthermore, it establishes a generalizable strategy for bottom-up engineering of biomimetic materials with programmable tissue tropism and modular functionality.
- 13 April 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (16) , 12321-12346
Self-Assembling Enveloped Virus-Mimicking Particle for Extrahepatic Targeting mRNA Delivery
Precise and efficient delivery of messenger RNA (mRNA) to extrahepatic tissues remains a major challenge in advancing mRNA-based therapeutics. Although enveloped viruses and virus-like particles (VLPs) serve as natural RNA delivery systems with varied extrahepatic targeting capabilities, their clinical translation is often hampered by bottlenecks in tunability, safety, immunogenicity, and scalability. Here, we developed a bottom-up self-assembling enveloped virus-mimicking particle (EVMP) composed of highly simplified yet high-performance virus-mimicking peptide (VMP) and tissue-targeting envelope phospholipids. By employing virtual screening via molecular dynamics simulation, directed evolution via key assembling domain mutation, strategic N-terminal fatty acylation modifications, and precise adjustments to envelope phospholipid composition, we achieved high-efficiency delivery of mRNA to organs such as the lungs and spleen. Notably, the optimized lung-targeted EVMP achieved transfection in 37% of total lung cells, including 73% of endothelial cells and 28% of immune cells. In a metastatic lung tumor model, the lead EVMP loaded with IL-12 mRNA effectively suppressed tumor progression. Notably, EVMP demonstrated excellent long-term biosafety and the capacity for repeated administration, owing to their minimal immunogenic profile. This biomimetic virus-mimicking nanoplatform represents a transformative advance in mRNA delivery technologies, enabling effective and safe mRNA-based therapy for extrahepatic diseases. Furthermore, it establishes a generalizable strategy for bottom-up engineering of biomimetic materials with programmable tissue tropism and modular functionality.
- Open Access
- 16 December 2025
- Published by Elsevier in Neurotherapeutics
- Vol. 23 (1) , e00813
Deep learning analysis of urine-derived stem cell mitochondrial morphology as a non-invasive Alzheimer’s disease biomarker
- 16 December 2025
- Published by Elsevier in Neurotherapeutics
- Vol. 23 (1) , e00813
Open AccessDeep learning analysis of urine-derived stem cell mitochondrial morphology as a non-invasive Alzheimer’s disease biomarker
- Open Access
- 3 July 2025
- Published by Springer Nature in Cell Death Discovery
- Vol. 11 (1) , 1-11
FL3 mitigates cardiac ischemia-reperfusion injury by promoting mitochondrial fusion to restore calcium homeostasis
This study aims to investigate the therapeutic potential of Flavagline3 (FL3) in mitigating myocardial ischemia-reperfusion (IR) injury, with a specific focus on its regulatory effects on mitochondrial fusion, mitochondrial-endoplasmic reticulum (ER) interactions, and calcium homeostasis in cardiomyocytes. Using a well-established myocardial IR injury model in mice and primary cardiomyocytes treated with FL3, the study assessed its impact on mitochondrial dynamics and intracellular signaling processes. The results demonstrated that FL3 effectively reduced myocardial apoptosis, infarct size, and cardiac dysfunction caused by IR injury. Mechanistically, FL3 promoted mitochondrial fusion in a mitofusin1 (MFN1)-dependent manner, preserving mitochondrial function under stress conditions and enhancing cellular resilience. Furthermore, FL3 facilitated mitochondrial-ER crosstalk, which played a critical role in modulating intracellular calcium levels by optimizing the transfer of calcium ions between these two organelles. This balanced regulation of mitochondrial dynamics and calcium homeostasis was associated with improved survival and functionality of cardiomyocytes following IR injury. These findings suggest that FL3 exerts robust cardioprotective effects through its ability to promote mitochondrial fusion, enhance mitochondrial-ER interactions, and maintain calcium homeostasis. As a result, FL3 holds promise as a potential therapeutic agent for reducing myocardial damage and dysfunction associated with IR injury, offering valuable insights into novel approaches for cardioprotection.
- 3 July 2025
- Published by Springer Nature in Cell Death Discovery
- Vol. 11 (1) , 1-11
Open AccessFL3 mitigates cardiac ischemia-reperfusion injury by promoting mitochondrial fusion to restore calcium homeostasis
This study aims to investigate the therapeutic potential of Flavagline3 (FL3) in mitigating myocardial ischemia-reperfusion (IR) injury, with a specific focus on its regulatory effects on mitochondrial fusion, mitochondrial-endoplasmic reticulum (ER) interactions, and calcium homeostasis in cardiomyocytes. Using a well-established myocardial IR injury model in mice and primary cardiomyocytes treated with FL3, the study assessed its impact on mitochondrial dynamics and intracellular signaling processes. The results demonstrated that FL3 effectively reduced myocardial apoptosis, infarct size, and cardiac dysfunction caused by IR injury. Mechanistically, FL3 promoted mitochondrial fusion in a mitofusin1 (MFN1)-dependent manner, preserving mitochondrial function under stress conditions and enhancing cellular resilience. Furthermore, FL3 facilitated mitochondrial-ER crosstalk, which played a critical role in modulating intracellular calcium levels by optimizing the transfer of calcium ions between these two organelles. This balanced regulation of mitochondrial dynamics and calcium homeostasis was associated with improved survival and functionality of cardiomyocytes following IR injury. These findings suggest that FL3 exerts robust cardioprotective effects through its ability to promote mitochondrial fusion, enhance mitochondrial-ER interactions, and maintain calcium homeostasis. As a result, FL3 holds promise as a potential therapeutic agent for reducing myocardial damage and dysfunction associated with IR injury, offering valuable insights into novel approaches for cardioprotection.
- Open Access
- 2 July 2025
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 36 (3) , 102620
Nanoparticle delivery of VEGF-B mRNA promotes T cell infiltration within tumor and triggers robust antitumor immunity
- 2 July 2025
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 36 (3) , 102620
Open AccessNanoparticle delivery of VEGF-B mRNA promotes T cell infiltration within tumor and triggers robust antitumor immunity
- 28 May 2025
- Published by American Diabetes Association in Diabetes
- Vol. 74 (8) , 1427-1440
Codelivery of NGFR100W and VEGFA mRNA Enhances Vascular and Neural Repair in Diabetic Peripheral Neuropathy
Diabetic peripheral neuropathy (DPN) poses significant clinical challenges due to progressive nerve degeneration and vascular insufficiency. To address both neural and vascular complications simultaneously, we employed an mRNA-based protein replacement therapy. In this study, leveraging mRNA template design, structure-based screening identified NGFR100W as a variant dissociating neuroprotective and nociceptive functions, demonstrating enhanced neuritogenic activity without pain sensitization. Additionally, transcriptome analysis of NGF mutants versus wild type further reveals the potential mechanism by which NGFR100W uncouples neuroprotective and nociceptive pathways. We cotransfected chemically modified NGFR100W mRNA and vascular endothelial growth factor A (VEGFA) mRNA, and the conditioned media collected from this transfection promoted endothelial cell migration, tubulogenesis, and neurite outgrowth. In a diabetic mouse model, combination therapy with lipid nanoparticle codelivery of NGFR100W and VEGFA mRNA significantly improved blood flow in the plantar region and mitigated nerve function decline compared with monotherapy. Histological analysis showed increased microvessel formation and higher intraepidermal nerve fiber density in treated mice. Our findings highlight the therapeutic potential of NGFR100W and VEGFA mRNA coadministration for DPN, suggesting that protein supplementation via mRNA could offer a novel strategy for clinical intervention in some chronic medical conditions. Article Highlights: We aimed to develop a dual-targeted mRNA-based therapy to address both neural degeneration and vascular insufficiency in diabetic peripheral neuropathy. We identified NGFR100W as a mutation that enhances neuritogenic activity without pain sensitization and investigated its transcriptome to explore its ability to uncouple neuroprotective and nociceptive pathways. Combination therapy using lipid nanoparticles for codelivery of NGFR100W and VEGFA mRNA improved blood flow, increased microvessel formation, and preserved nerve function in a diabetic mouse model. This approach, which combines structure-based design and mRNA therapy, offers a novel strategy for decoupling protein functions and developing therapeutic molecules with specific functionalities.
- 28 May 2025
- Published by American Diabetes Association in Diabetes
- Vol. 74 (8) , 1427-1440
Codelivery of NGFR100W and VEGFA mRNA Enhances Vascular and Neural Repair in Diabetic Peripheral Neuropathy
Diabetic peripheral neuropathy (DPN) poses significant clinical challenges due to progressive nerve degeneration and vascular insufficiency. To address both neural and vascular complications simultaneously, we employed an mRNA-based protein replacement therapy. In this study, leveraging mRNA template design, structure-based screening identified NGFR100W as a variant dissociating neuroprotective and nociceptive functions, demonstrating enhanced neuritogenic activity without pain sensitization. Additionally, transcriptome analysis of NGF mutants versus wild type further reveals the potential mechanism by which NGFR100W uncouples neuroprotective and nociceptive pathways. We cotransfected chemically modified NGFR100W mRNA and vascular endothelial growth factor A (VEGFA) mRNA, and the conditioned media collected from this transfection promoted endothelial cell migration, tubulogenesis, and neurite outgrowth. In a diabetic mouse model, combination therapy with lipid nanoparticle codelivery of NGFR100W and VEGFA mRNA significantly improved blood flow in the plantar region and mitigated nerve function decline compared with monotherapy. Histological analysis showed increased microvessel formation and higher intraepidermal nerve fiber density in treated mice. Our findings highlight the therapeutic potential of NGFR100W and VEGFA mRNA coadministration for DPN, suggesting that protein supplementation via mRNA could offer a novel strategy for clinical intervention in some chronic medical conditions. Article Highlights: We aimed to develop a dual-targeted mRNA-based therapy to address both neural degeneration and vascular insufficiency in diabetic peripheral neuropathy. We identified NGFR100W as a mutation that enhances neuritogenic activity without pain sensitization and investigated its transcriptome to explore its ability to uncouple neuroprotective and nociceptive pathways. Combination therapy using lipid nanoparticles for codelivery of NGFR100W and VEGFA mRNA improved blood flow, increased microvessel formation, and preserved nerve function in a diabetic mouse model. This approach, which combines structure-based design and mRNA therapy, offers a novel strategy for decoupling protein functions and developing therapeutic molecules with specific functionalities.
- Open Access
- 27 April 2025
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 24 (6) , 2832-2845
Multi-omics Analysis Sheds Light on the Extracellular Role of PCMT1
Proteins are constantly damaged by intracellular and extracellular factors, particularly under stress conditions, leading to an accumulation of modified proteins such as isoaspartate (isoD), which is linked to aging and various diseases. The repair enzyme PCMT1 (protein-l-isoaspartate o-methyltransferase) specifically restores isoD residues to aspartate, preventing abnormal protein functions. Despite its importance, its role in non-neural tissues remains underexplored. This study employed isoD-proteomics, global proteomics, and transcriptomics on Pcmt1 knockout (KO) and wild-type (WT) mice, revealing significant gene and protein changes in various KO tissues, enriched in extracellular and membrane-related categories, highlighting genome-proteome correlations. IsoD-carrying proteins were increased in KO tissues, predominantly consisting of long-lived proteins. Additionally, the proteomic analysis of PCMT1-overexpressing cells identified interacting proteins mainly in extracellular and membrane-related categories. These findings revealed both tissue-specific and shared roles of PCMT1, emphasizing its importance in maintaining protein integrity under physiological and stress conditions while also uncovering an unexpected extracellular function of PCMT1.
- 27 April 2025
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 24 (6) , 2832-2845
Open AccessMulti-omics Analysis Sheds Light on the Extracellular Role of PCMT1
Proteins are constantly damaged by intracellular and extracellular factors, particularly under stress conditions, leading to an accumulation of modified proteins such as isoaspartate (isoD), which is linked to aging and various diseases. The repair enzyme PCMT1 (protein-l-isoaspartate o-methyltransferase) specifically restores isoD residues to aspartate, preventing abnormal protein functions. Despite its importance, its role in non-neural tissues remains underexplored. This study employed isoD-proteomics, global proteomics, and transcriptomics on Pcmt1 knockout (KO) and wild-type (WT) mice, revealing significant gene and protein changes in various KO tissues, enriched in extracellular and membrane-related categories, highlighting genome-proteome correlations. IsoD-carrying proteins were increased in KO tissues, predominantly consisting of long-lived proteins. Additionally, the proteomic analysis of PCMT1-overexpressing cells identified interacting proteins mainly in extracellular and membrane-related categories. These findings revealed both tissue-specific and shared roles of PCMT1, emphasizing its importance in maintaining protein integrity under physiological and stress conditions while also uncovering an unexpected extracellular function of PCMT1.
- Open Access
- 4 March 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36 (7) , 1278-1294
Repair of Isoaspartyl Residues by PCMT1 and Kidney Fibrosis
Key Points: Protein L-isoaspartyl/D-aspartyl methyltransferase (PCMT1) expression was lower in fibrotic kidney tubule, and tubule-specific deficiency worsened the pathogenesis and progression of CKD. Decreased PCMT1 levels inversely correlated with kidney function, highlighting its potential as a diagnostic and therapeutic target. PCMT1 enzymatically regulated the deamidation and protein stability of TGF- β receptor 2, inhibited TGF- β 1/Smad signaling, and impeded the profibrotic process. Background: Kidney fibrosis, the excessive accumulation and dysregulated remodeling of the extracellular matrix, is the principal pathophysiologic process in CKD. Protein L-isoaspartyl/D-aspartyl methyltransferase (PCMT1) is crucial in repairing post-translational modifications of L-isoaspartyl residues, which are important for extracellular matrix proteins because of their low turnover rate and susceptibility to accelerating factors. This study aimed to reveal a novel role of PCMT1 in kidney fibrosis. Methods: Kidney tissues from mice and humans were evaluated for PCMT1 expression and its association with fibrosis and kidney function. PCMT1's effects on the TGF- β 1/Smad signaling were analyzed, and its functional role was assessed in tubule-specific Pcmt1 knockout murine models of kidney fibrosis. The ability of secreted PCMT1 to repair L-isoaspartyl residues on the ectodomain of TGF- β receptor 2 (TGFBR2) was investigated using immunoprecipitation, gene lentivirus overexpression or knockout, and post-translational modification mass spectrometry. Results: PCMT1 expression was decreased in the tubules of human kidney biopsies from patients with CKD and murine fibrosis models. Renal tubule-specific PCMT1 deficiency in murine kidney fibrosis models worsened tubular injury, extracellular matrix protein deposition, myofibroblast activation, and TGF- β 1/Smad signaling overactivation. Mechanistically, PCMT1 was unconventionally secreted and enzymatically inhibited TGF- β 1–induced extracellular matrix protein deposition in vitro . PCMT1 interacted with TGFBR2, reversing N63 deamidation on its ectodomain, which triggered TGFBR2 ubiquitination and degradation. PCMT1 supplementation in kidneys decreased TGFBR2 levels, attenuated TGF- β 1/Smad overactivation, and impeded the profibrotic process. Conclusions: Our study highlights the importance of PCMT1 in maintaining extracellular matrix homeostasis and mitigating kidney fibrosis by regulating TGFBR2 deamidation and its protein stability, suppressing the TGF- β 1/Smad signaling.
- 4 March 2025
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 36 (7) , 1278-1294
Open AccessRepair of Isoaspartyl Residues by PCMT1 and Kidney Fibrosis
Key Points: Protein L-isoaspartyl/D-aspartyl methyltransferase (PCMT1) expression was lower in fibrotic kidney tubule, and tubule-specific deficiency worsened the pathogenesis and progression of CKD. Decreased PCMT1 levels inversely correlated with kidney function, highlighting its potential as a diagnostic and therapeutic target. PCMT1 enzymatically regulated the deamidation and protein stability of TGF- β receptor 2, inhibited TGF- β 1/Smad signaling, and impeded the profibrotic process. Background: Kidney fibrosis, the excessive accumulation and dysregulated remodeling of the extracellular matrix, is the principal pathophysiologic process in CKD. Protein L-isoaspartyl/D-aspartyl methyltransferase (PCMT1) is crucial in repairing post-translational modifications of L-isoaspartyl residues, which are important for extracellular matrix proteins because of their low turnover rate and susceptibility to accelerating factors. This study aimed to reveal a novel role of PCMT1 in kidney fibrosis. Methods: Kidney tissues from mice and humans were evaluated for PCMT1 expression and its association with fibrosis and kidney function. PCMT1's effects on the TGF- β 1/Smad signaling were analyzed, and its functional role was assessed in tubule-specific Pcmt1 knockout murine models of kidney fibrosis. The ability of secreted PCMT1 to repair L-isoaspartyl residues on the ectodomain of TGF- β receptor 2 (TGFBR2) was investigated using immunoprecipitation, gene lentivirus overexpression or knockout, and post-translational modification mass spectrometry. Results: PCMT1 expression was decreased in the tubules of human kidney biopsies from patients with CKD and murine fibrosis models. Renal tubule-specific PCMT1 deficiency in murine kidney fibrosis models worsened tubular injury, extracellular matrix protein deposition, myofibroblast activation, and TGF- β 1/Smad signaling overactivation. Mechanistically, PCMT1 was unconventionally secreted and enzymatically inhibited TGF- β 1–induced extracellular matrix protein deposition in vitro . PCMT1 interacted with TGFBR2, reversing N63 deamidation on its ectodomain, which triggered TGFBR2 ubiquitination and degradation. PCMT1 supplementation in kidneys decreased TGFBR2 levels, attenuated TGF- β 1/Smad overactivation, and impeded the profibrotic process. Conclusions: Our study highlights the importance of PCMT1 in maintaining extracellular matrix homeostasis and mitigating kidney fibrosis by regulating TGFBR2 deamidation and its protein stability, suppressing the TGF- β 1/Smad signaling.
- Open Access
- 30 January 2025
- Published by Elsevier in Molecular Cell
- Vol. 85 (3) , 638-651.e9
The mitochondrial DNAJC co-chaperone TCAIM reduces α-ketoglutarate dehydrogenase protein levels to regulate metabolism
- 30 January 2025
- Published by Elsevier in Molecular Cell
- Vol. 85 (3) , 638-651.e9
Open AccessThe mitochondrial DNAJC co-chaperone TCAIM reduces α-ketoglutarate dehydrogenase protein levels to regulate metabolism